PsA Trial Design Can Improve Patient Safety, Outcomes

Drs. Coates and Ogdie also expressed concerns about the ethics and value of including placebo arms in trials. Both emphasized the need to design studies with active comparator arms and measures of deeper response. In addition, phase 4 trials and longitudinal observational studies in PsA would better address safety than long-term extension studies, Dr. Coates said.

Vanessa Caceres is a medical writer in Bradenton, Fla.

References

Orbai A-M, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017 Apr;76(4):673–680.
European Medicines Agency. Letter of support for Minimal Disease Activity Score as primary outcome instrument for clinical studies in psoriatic arthritis. 2022 Feb 22. https://www.ema.europa.eu/en/documents/other/letter-support-minimal-disease-activity-score-mda-primary-outcome-instrument-clinical-studies_en.pdf.

The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Minimizing Disease Activity in Psoriatic Arthritis

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Related Articles